Table 2 Limit of blank: data for the 12 participating laboratories.

From: Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Lab

A

B

C

D

E

F

G

H

I

J

K

L

Final BCR::ABL1 LoB (95%)

0

0

0

0

0

0

0

0

0

0.41

2.35

2.57

Final BCR::ABL1 LoB (90%)

–

–

–

–

–

–

–

–

–

0

0.6

2.17

Final BCR::ABL1 LoB (85%)

–

–

–

–

–

–

–

–

–

–

0

1.95

Final BCR::ABL1 LoB (50%)

–

–

–

–

–

–

–

–

–

–

–

0.79

Total BCR::ABL1 replicates

120

120

120

120

120

120

90

120

120

120

120

120

No. of negative BCR::ABL1 replicates

120

120

120

120

120

120

90

119

119

117

110

3

% Negative BCR::ABL1 replicates

100

100

100

100

100

100

100

99.2

99.2

97.5

91.7

2.5

Max BCR::ABL1 copy number

0

0

0

0

0

0

0

1.44

2.15

2.67

2.9

4.25

  1. Laboratories A–I have a likelihood of ≤5% that a true BCR::ABL1 negative sample will give a result greater than zero. Laboratories J, K, and L have a likelihood ranging from 10–50% (indicated in bold) that a true BCR::ABL1 negative sample will give a result greater than zero.
Back to article page